Paragonix introduces the PancreasPak™, the first FDA-cleared device for preserving donor pancreases

Paragonix Technologies, a leader in organ transplant solutions, is introducing the PancreasPak™ Organ Preservation System, the first FDA-cleared device specifically designed for protecting and monitoring donor pancreases during transport. 

Pre-orders for this innovative technology will begin on June 27, 2024, with full availability expected by September 1, 2024.

The PancreasPak™ System is set to revolutionize pancreatic transplantation, a field that has seen limited advancements.

Leveraging the principles of Paragonix’s successful SherpaPak® Cardiac Transport System—used in one-third of US cases—the new device provides advanced tracking and control. 
It maintains the pancreas at an optimal temperature range of 4-8°C for up to 21 hours, ensuring a controlled environment. 

This approach aligns with the proven benefits of the SherpaPak®, which include extended ischemic times, reduced post-transplant complications, and improved 2-year patient survival rates.

The introduction of the PancreasPak™ System is expected to significantly enhance pancreas preservation, allowing for better organ viability and improved patient outcomes. 

This advancement underscores Paragonix Technologies' commitment to pushing the boundaries of organ transplantation and offering specialized support for transplant and donor patients.

The PancreasPak™, having received FDA 510(k) clearance, will be available for commercial pre-order starting in late June.

Source: https://www.paragonixtechnologies.com/news/paragonix-unveils-pancreaspak-tm-the-worlds-first-fda-cleared-preservation-device-for-donor-pancreas-transplantation